Dr. Reddy’s Laboratories Ltd has agreed to acquire the U.S. generic prescription product portfolio of Mayne Pharma Group Ltd for $105 million, subject to completion of customary closing conditions. The portfolio includes 45 commercial products, four pipeline products, and 40 approved non-marketed products, including many generic products that are focused on women’s health. The acquisition complements Dr. Reddy’s U.S. retail prescription pharmaceutical business with limited competition products, providing a significant foothold in the women’s health space.

Mayne Pharma Group reported a total revenue of $111 million for the acquired portfolio in the financial period ending June 30, 2022. Under the terms of the agreement, Dr. Reddy’s will get the portfolio for an upfront payment of approximately $90 million in cash, with additional contingent payments of up to $15 million, consideration towards inventory, and credits for certain accrued channel liabilities to be determined on the closing date.